A roundup of the latest developments for drug delivery of parenteral drugs.
Sep 5, 2012
By:
Patricia Van Arnum
A roundup of the latest developments for drug delivery of parenteral drugs.
|
A look at PharmaCheck, a field-based tool in development that uses microfluidic chip technology for assessing the quality of medicine in the developing world.
Sep 5, 2012
By:
Patricia Van Arnum
A look at PharmaCheck, a field-based tool in development that uses microfluidic chip technology for assessing the quality of medicine in the developing world.
|
The Generic Drug User Fee Act seeks to improve and enhance regulatory activities, including achieving parity of inspections between foreign and domestic drug-manufacturing sites for both finished dosage forms and APIs of generic drugs.
Sep 5, 2012
By:
Patricia Van Arnum
The Generic Drug User Fee Act seeks to improve and enhance regulatory activities, including achieving parity of inspections between foreign and domestic drug-manufacturing sites for both finished dosage forms and APIs of generic drugs.
|
Sep 4, 2012
By:
Patricia Van Arnum
Bristol-Myers Squibb has initiated a voluntary recall of 10 lots of BiCNU (carmustine for injection) previously manufactured by Ben Venue Laboratories, a former, third-party contract manufacturer for the company, to the user level.
|
Industry and academia advance novel approaches for achieving enanioselectivity.
Sep 2, 2012
By:
Patricia Van Arnum
Industry and academia advance novel approaches for achieving enanioselectivity.
|
|
Researchers from the University of Cambridge have developed injectable, reformable, and spreadable hydrogels capable of delivering sustained release of the proteins they contain for up to six months.
Sep 2, 2012
By:
Patricia Van Arnum
Researchers have developed injectable, reformable, and spreadable hydrogels capable of delivering sustained release of the proteins they contain for up to six months.
|
|
Industry experts share perspectives on analytical instrumentation, methods, and data analysis.
Sep 2, 2012
By:
Patricia Van Arnum
Industry experts share perspectives on analytical instrumentation, methods, and data analysis.
|
|
Advances in targeted drug delivery and customized release profiles are key industry goals.
Sep 2, 2012
By:
Patricia Van Arnum
Advances in targeted drug delivery and customized release profiles are key industry goals.
|
The author discusses the key provisions of GDUFA as they relate to the pharmaceutical supply chain, including parity of inspections between domestic and foreign sites for both finished dosage forms and APIs of generic drugs.
Sep 1, 2012
By:
Patricia Van Arnum
The author discusses the key provisions of GDUFA as they relate to the pharmaceutical supply chain, including parity of inspections between domestic and foreign sites for both finished dosage forms and APIs of generic drugs.
|
|
